Increasing evidence suggests that angiotensin II (Ang II) may act as a growth factor for the heart. However, direct effects 
T he renin-angiotensin system plays a critically important role in the control of cardiovascular and renal homeostasis. 12 Previously, this system has been considered to be an endocrine system, in which angiotensinogen is produced in the liver and secreted into the systemic circulation, where the successive proteolytic cleavages by renin and angiotensin converting enzyme (ACE) occur to produce the biologically active peptide angiotensin II (Ang II). 1, 2 Recently, however, there is accumulating evidence for the existence of an independent tissue (local) reninangiotensin system in several organs. This concept is supported by evidence derived from biochemical, immunohistochemical, and molecular biological demonstration of all components of the renin-angiotensin system, including renin, angiotensinogen, ACE, angiotensin I (Ang I), Ang II, and Ang II receptors in local tissues, including the heart and blood vessels. Besides its potent vasoconstrictive effect, Ang II has been suggested to work as an autocrine/paracrine factor regulating growth of local tissues such as blood vessel, kidney, and heart. [3] [4] [5] [6] [7] The direct growth effect of Ang II has been extensively characterized in vascular smooth muscle cells, where Ang II has been shown to promote hypertrophy in vitro.8-10 Interestingly, Ang II also causes hyperplasia in some smooth muscle cells in culture, such as the aorta of spontaneously hypertensive rats or the renal arteri- (Fig 1, A) . The (Fig 2, B) . Losartan (Fig 1, A) . Interestingly, Ang II caused a significant increase in [3H]thymidine uptake over 24 hours in these cells (Fig 1, B) , although the magnitude of increase caused by Ang II was 8% to 10% of that caused by 20% fetal calf serum (data not shown).
To confirm Ang Il-induced DNA synthesis in nonmyocytes, the cells were labeled with the thymidine analogue BrdU, and a double immunofluorescent analysis was performed using anti-BrdU antibody and antisarcomeric myosin antibody (Fig 3) . We deliberately used a mixed culture of myocytes and nonmyocytes for this analysis to examine both cell types in the same microscopic field. In control cells cultured in the serumfree medium for 48 hours, no staining was observed by anti-BrdU antibody in any of the myosin-positive cells (Fig 3, a and c (Fig 4, B) . Ang II caused a 30% increase in cell number over 24 hours, and this increase was com-A pletely prevented by losartan but not by PD123319 (Fig 4,  B) the others showed moderately elevated expression even at 2 hours.
Recently Roux et aP411 reported that, in the absence of serum, the Fos protein could not be translocated into nucleus and stayed in cytoplasm in rat embryonic fibroblasts and mouse fibroblast cell lines. Therefore, we examined whether growing the cardiac myocytes and nonmyocytes in serum-free conditions actually leads to translocation of Fos protein to the nucleus after its synthesis in the cytoplasm in response to Ang I stimulation. Double immunofluorescence staining was performed on a mixed cell culture using anti-Fos and anti-sarcomeric myosin antibodies. Both myosin-positive cells (Fig 6, a through c ; arrowheads) and myosinnegative cells (arrows) expressed Fos protein 1 hour after treatment with Ang II (Fig 6, a) . No specific Fos signals were observed in nontreated control culture (Fig   6, d) 
Induction of c-fos by Ang II Is Mediated Primarily by A T, Receptors
Ang II induced c-fos expression in a dose-dependent manner in cardiac myocytes (Fig 7, A) . The induction of c-fos was detected at 10 pM, and maximum induction was observed at approximately 100 nM. 
Effects of Angiotensin Metabolites on c-fos Induction
Recently, the existence of the local renin-angiotensin system has been reported in various tissues, including the rat heart.3-6 To identify the biological activity of several metabolites of the renin-angiotensin system, we examined c-fos inducibility by exogenously applying angiotensin-related peptides to the cardiac myocyte. Among the Ang II degradation products, Ang III (10 nM) induced c-fos expression almost as potently as did Ang II (Fig 8, lane 4) . However, the aminopeptidase cleavage products Ang II-(3-8) (100 nM) and Ang II-(4-8) (100 nM) did not induce c-fos (lanes 5 (Fig 9, A) . Although ANF and skeletal a-actin mRNAs were detectable under control conditions in these neo- mRNA in response to Ang II stimulation because TGF-f3l is known to be a potent inducer of the fetal genes in neonatal rat cardiac myocytes.33 As shown in Fig 9, B , a significant induction of angiotensinogen mRNA and TGF-3,1 mRNA was observed 6 hours after Ang II treatment, and this effect appeared more pronounced at 24 hours.
Increased Expression of "Late" Genes Is Mediated by AT, Receptors
We next examined whether increase in "late" genes by Ang II stimulation was mediated by AT1 or AT2 receptors. Ang Il-induced increases in mRNAs encoding skeletal a-actin, ANF, TGF-f3,, and angiotensinogen were significantly suppressed by losartan but not by PD123319 (Fig 10 and data heart,4 6 a direct proof for this hypothesis awaits a study using cultured adult myocytes. Interestingly, Moalic et a152 have reported that infusion of Ang II did not induce c-fos or c-myc in an isolated perfused adult rat heart, presumably because of the absence of Ang II receptors in the adult rat heart. Very recently, however, Dostal and Baker53 have reported that chronic infusion of Ang II causes cardiac hypertrophy and that this is prevented by losartan in adult rat hearts. It remains to be determined whether our in vitro results using neonatal cells may apply for the adult heart in vivo.
It is of interest that Ang II increases the expression of the angiotensinogen gene. This raises the possibility that Ang II may initiate a positive-feedback regulation of cardiac growth. Ang II also increases expression of the TGF-/31 gene. TGF-fl1 is known to induce "fetal" genes in cardiac myocytes33 and enhance the synthesis of the extracellular matrix by fibroblasts.25 54Ang II has been shown to induce platelet-derived growth factor35 and TGF-J3155 in smooth muscle cells. It is likely that Ang II may induce other growth factor genes in cardiac myocytes as well. It is possible that the mitogenic effect of Ang II on nonmyocytes may be due to an enhanced autocrine/paracrine production of growth factors by Ang II stimulation.
In summary, we have demonstrated that Ang II causes hypertrophy of cardiac myocytes and mitogenesis of nonmyocytes (primarily fibroblasts) via AT1 receptor stimulation. Elucidation of the mechanisms of Ang Il-induced cardiac growth deserves further investigation because Ang II is clearly emerging as one of the most important mediators of cardiac hypertrophy in vivo.
